CA1106758A - Process for the total determination of hormones and pharmaceuticals by enzymatic hydrolysis and use of immobilized antibodies - Google Patents
Process for the total determination of hormones and pharmaceuticals by enzymatic hydrolysis and use of immobilized antibodiesInfo
- Publication number
- CA1106758A CA1106758A CA302,081A CA302081A CA1106758A CA 1106758 A CA1106758 A CA 1106758A CA 302081 A CA302081 A CA 302081A CA 1106758 A CA1106758 A CA 1106758A
- Authority
- CA
- Canada
- Prior art keywords
- hormones
- pharmaceuticals
- determination
- antibody
- enzymatic hydrolysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
Abstract
ABSTRACT OF THE DISCLOSURE
Disclosed is a method for the total determination of hormones and pharmaceuticals partially bound to specific or non-specific proteins, by the enzymatic hydrolysis of the bonding proteins, the reaction of the hormones or pharmaceuticals with an antibody and the radioimmunological determination of the hormones and pharmaceuticals, char-acterized by the fact that the immobilized antibodies are used.
Disclosed is a method for the total determination of hormones and pharmaceuticals partially bound to specific or non-specific proteins, by the enzymatic hydrolysis of the bonding proteins, the reaction of the hormones or pharmaceuticals with an antibody and the radioimmunological determination of the hormones and pharmaceuticals, char-acterized by the fact that the immobilized antibodies are used.
Description
~o~5~ K 12 190 IMpRovEMæNT IN THE PROCESS FOR THE TOTAL
DETERMINATION OF HORMONES AND PHARMACEUTICALS
TECHNICAL FIELD OF THE INVENTION
~ . .
The invention concerns a process for the total determination of hormones and pharmaceuticals. More specifically, the invention relates to the total determina-tion of hormones or pharmaceuticals bonded partially to specific or non-specific bonding proteins by the enzymatic hydrolysis of the bonding proteins, the reaction of the hormones or pharmaceuticals with an antibody and the radio-immunological determination of hormones or pharmaceuticals.
BACKGROUND OF THE PRIDR ART
Various methods for the total determination of hormones or pharmaceuticals present in human serum, bonded partially to specific or non-specific bonding proteins, are known. In recent years, the relatively new radioimmunological techniques have contributed sub- ;
stantially to the exact determination of hormones.
Detailed descriptions of radioimmunoassays are found, for example, in Clinical Chemistry, Vol. 19, No. 2, 1973, p. 145. In Clinical Chemistry, Vol. 19, No. 12, 1973, p. 1339, and Clinical Chemistry, Vol 21, No. 7, 1975, p. 829, radioimmunological techniques are described in which an antibody enclosed in a gel is used.
The inclusion of the antibody in gel is considered advan-tageous by th~s authors, becuase in this manner inter-~' .. ..
o~s~
DETERMINATION OF HORMONES AND PHARMACEUTICALS
TECHNICAL FIELD OF THE INVENTION
~ . .
The invention concerns a process for the total determination of hormones and pharmaceuticals. More specifically, the invention relates to the total determina-tion of hormones or pharmaceuticals bonded partially to specific or non-specific bonding proteins by the enzymatic hydrolysis of the bonding proteins, the reaction of the hormones or pharmaceuticals with an antibody and the radio-immunological determination of hormones or pharmaceuticals.
BACKGROUND OF THE PRIDR ART
Various methods for the total determination of hormones or pharmaceuticals present in human serum, bonded partially to specific or non-specific bonding proteins, are known. In recent years, the relatively new radioimmunological techniques have contributed sub- ;
stantially to the exact determination of hormones.
Detailed descriptions of radioimmunoassays are found, for example, in Clinical Chemistry, Vol. 19, No. 2, 1973, p. 145. In Clinical Chemistry, Vol. 19, No. 12, 1973, p. 1339, and Clinical Chemistry, Vol 21, No. 7, 1975, p. 829, radioimmunological techniques are described in which an antibody enclosed in a gel is used.
The inclusion of the antibody in gel is considered advan-tageous by th~s authors, becuase in this manner inter-~' .. ..
o~s~
-2-actions with molecules of high molecular weight are excluded. However, these known working processes are not intended for total hormone determination. Nevertheless, from a medical standpoint,total hormone determination is essential.
Methods of the total determination of hormones through the enzymatic hydrolysis of the bonding proteins and with radioimmunological techniques are known from J.Clin. Endocrinol. Metab. 42, 189, 1976 and Clinical Chemistry, Vol 22, No. 11, 1976, p. 1850. These articles show that enzymatic cleavage has significant advantages \ compared with methods used heretofore, such as, for example, solvent extraction and heat denaturation. Advantages specifically named are the facts that extraction with organic solvents and the chromatographic purification of samples are eliminated,thatthe time and expense of the determination is reduced, that scinitallation counting in the liquid is eliminated, that specificity and accuracy is improved, that the method of determination can be automated, and that the method is universally applicable.
However, the enzyme used to hydrolyze the bonding protein also attacks the antibody introduced in the next working step and destroys the latter. For this reason, the enzyme must be deactivated prior to the addition of said antibody. Inactivation of enzymatic activity is pos-sible in a number of ways, for example, the enzyme can be denaturated by a substantial change in the pH value or by a heat effect.
However, this denaturization step is extremely disadvantageous. It requires either the addition of supplemental chemicals which introduces still more factors of interference in the system or it re~uires long periods of time for heat denaturization. The heat effect must last for approximately 5 minutes, while the cooling period amounts to approximately 15 minutes. This denaturization step thus represents a substantial hindrance in the automation of the determination. Further, depending on the system applied, specifically the enzyme used, different types of dena-turization must be performed, which opposes the general applicability of -the method of determination and its automation.
SUMMARY OF THE INVENTION
To avoid the difficulties of the prior art, the present invention creates a method for the total determina-tion of hormones and pharmaceuticals in which no denaturing step is necessary. Thus, it is an object of the invention to renderthe method of determination universally applic-able, to reduce the time and expense of the determination and to make possible the automation of the determination.
According to the invention, the object is attained \ by a method for the total determination of hormones and pharmaceuticals partially bound to specific or non-specific proteins, by the enzymatic hydrolysis of the bonding pro-teins, the reaction of said hormones or pharmaceuticals with an antibody and the radioimmunological determination of the hormones and pharmaceuticals, characterized by the fact that immobilized antibodies are used.
The antibody is preferably enclosed in a polymer gel. Acrylamide polymers and acrylamide copolymers are particularly preferred as the polymer gel. Specific advan-tages of copolymers are described in greater detail in Applicant's related application The application of immobilized antibodies pro-tects the an-tibodies from the enzyme. The antibodies are included in the polymer matrix which the enzyme, because of its size, cannot penetrate. As a resul-t of this simple and elegant measure in the process of the invention, the step of denaturing the enzyme may be eliminated. The process thus involves significantly less labor and requires less time. The method is universally applicable to different systems, because the specific enzyme denaturiza-tion is eliminated. Furthermore, the process of the invention is of particular importance, as it lends itself especially well to the automation of the determination.
6'7~
DETAIiED DESCRIPTION OF THE INVENTION
The method of the invention is suitable for the determination of different hormones and pharmaceu-ticals, which are present in the serum or the plasma in a state bound in part to specific or non-specific bonding proteins.
The hormones to be determined are thyroid hormones, particularly thyroxine and tri-iodothyroxin, the steroid hormones such as cortisol, testosterone, progesterone, estron, estradiol and estriol and the heart glycosides, such as digitoxin and digoxin. Further, vi-tamins, particularly Vitamin B12 and folic acid, as well as \ pharmaceuticals with strong protein bonds, such as, for example, anti-coagulants, dicumarol, analgetics and salycilates, may be determined.
In the execution of the determination, the serum or plasma containing the hormone or pharmaceutical is placed in contact with a solution of an enzyme, the enzyme hydrolytically cleaving the bonding protein. The choice of the enzyme is directed by the specific bonding protein.
For example, the following enzymes may be used depending on the system: aminopeptidase, bromelin, carboxypeptidase, chymotripsin, elastase, ficin, leucinaminopeptidase, lipase, pancreatin, papin, pepsin, pronase, protease, proteunase, thermolysin and trypsin. For the determination of hormones such as thyroxin and cortisol, proteolytic enzymes such as proteinase, pronase or pepsin are particularly suitable.
The reaction of the sample wi-th enzymatic solution can be performed on a controlled temperature means at temperatures around 35C or a room temperature. The period of time required for the enzymatic hydrolysis of the protein depends on the enzyme used and is between 15 minutes and 4 hours, in many cases between 15 and 30 minutes.
Following the hydrolysis of the protein, the sample is mixed with a marked indicator hapten and added to the immobilized antibody.
The addition is effected with the aid of a multi-channel piston pump. With the pump running in reverse, the reaction ]mixture is suctioned quantitatively into s~
small columns, said columns containing the immobilized antibody. ~n especially suitable apparatus for this is described in Applicant's copending application Subsequently, a rest interval is provided for the reaction of the marked and unmarked substance to be deter-mined with the immobilized antibody.
A final extraction with water or a buffer solu-tion yields the separation of haptenebound to the antibody and the free haptene. The resi~dual radioactivity in the extract or the column is a measure o~ the concentration of \ the substance to be determined. The radioimmunological principle is known, for example, from D. S. Skelley et al, Clinical Chemistry, Vol. 19, No. 2, 1973, p. 146ff.
Alternative methods of determination, such as fluoroimmunological determination or determination by enzymatic marking, may also be used.
The synthesis of antigenes, the production of antisera, for example, through the immunication of rabbits and the isolation and immobilization of antibodies, are known ~see for example, D. S. Skelley et al., Clinical Chemistry, Vol. 19, No. 2, 1973, p. 146ff.
Immobilized antibodies are produced, for example, by adding a solution of the antibody to a monomer mixture.
The mixture is subjected to conditions of free radical polymerization and the polymer obtained is comminuted, washed and dried. Acrylamide is particularly suitable as the monomer. By copolymerizing the acrylamide with acryl derivatives with different functional groups, such as, for example, acrylic acid, methacrylic acid and methacrylamide, advantageous variations of the matrix may be obtained. Through the addition of copolymers, particu-larly the hydrophobicity and the charge of the matrix, can be affected and thus, the reaction of the antibody with the hormone or pharmaceutical to be determined, influenced.
In order to obtain a suitable pore size of the polymer matrix, the monomer concentration is varied. A
monomer concentration in the range of about 20% results in a pore size of about 7 to 10 A.
The use of an ~on-exchanged polymer matrix is also advantageousO The buffer action obtained by the ion exchange can be used to alter the p~ values in the sample to be determined~ An advantageous system is, for example, a copolymer of acrylamide and 20 to 60% acrylic acid and/
or methacrylic acid, prepared from an approximately 20%
monomer solution in which at least part of the acid groups are converted into the corresponding alkali or alkaline earth salts.
The invention will be explained hereafter in more detail with the aid of examples \ Example 1 '~ Determination of Thyroxin by Enzymatic Hydrolysis with Pronase 1~ The antigen synthesis was performed beginning with thyroxine ethyl ester and coupling on albumin with carbodiimide. The antibody was produced through the immunization of rabbits.
The antibody was then enclosed in polymer gel.
An acrylamide monomer with a concentration of 2.9 mole/l was used. For the initial mixture, 5 g acrylamide and 1.25 g N,N'-methylene-bis-acrylamide were dissolved in a beaker in 24 ml of a phosphate buffer with a pH value of 7.2.
Following the admixture of the antiserum in 1 ml phosphate buffer, the reaction was started with 0.15 g riboflavin and 0.10 ml N,N,N',N'-tetramethylethylenediamine and irradiated with W light. ~uring the irradiation period of 45 minutes the temperature was maintained at less than 50C. The gel block was subsequently comminu-ted, washed with distilled water, and dried.
The zero serum was produced by reacting 1 ml serum and a pronase solution with a concentration of 2 mg/
ml for 30 minutes at 35C. Subsequently, 2 g of an ion exchange resin (Amberlite 400) were added.
After this, 50 ~1 of the zero serum with a content of 18 g thyroxine per 100 ml were reacted with 350 ~1 enzyme solution with a concentration of 2 mg per ml for 30 minutes at a temperature of 35C.
' ' . .
- ~' ~CI 675~3 To L00 ~1 of this solution, 700 ~1 of the tracer solution w ~h a content of 5.2 ng/ml of radioactive marked thyroxine and 50 ~1 buffer solution with a pH value of 7.2 were added. 350 ~1 of this solution were added to 60 mg of the antibody gel. The incubation period was 30 minutes, the temperature 22~C. ~ubsequently, the solution was extracted for 5 minutes~with a pumping rate of 0.5 ml/min.
A dose effect curve for thyroxine was established with thyroxine solutions having concentrations of 5 ng, 10 ng, 20 ng and 50 ng per 100 ml. These solutions were reacted with 350 ~1 enzyme solution (concentration 2 mg/ml) for 30 minutes at a temperature of 35C.
To the 100 ~1 of this solution, 700 ~1 tracer solution (5.2 ng/ml) and in place of the buffer, 50 ~1 zero serum were added.
The evaluation resulted in a recovery of 99~.
Example 2 Total Determination of Thyroxine by Enzymatic Hydrolysis with Proteinase The working procedure of Example 1 was followed, but instead of the pronase solution, a proteinase solu-tion with a concentration of 2 mg/ml was used.
The serum applied consisted of a zero serum with a content of 6 mg per 100 ml.
The recovery was 98.5%.
Example 3 Total Determination of Cortisol by Enzymatic Hydrolysis with Pronase The procedure of Example 1 was followed, but a 30 serum containing 18 ~g cortisol per 100 ml was used. As the tracer soiution, a solution of radioactive marked cortisol in a concentration of 0.15 ng/ml was used. The antibody used was prepared by the synthesis of cortisol-C3-oxime and coupling at albumin with mixed anhydride and antibody procluction through the immunication of rabbits.
The recovery was 97%.
, :, ., ., ~. . --~6~7S~
Example 4 Total Determination of Cortisol by Enzymatic Hydrolysis with Proteinase The working procedure of Example 3 was followed, but the serum contained 6 ~g cortisol per 100 ml and a proteinase solution with a conc:entration of 2 mg/ml was used.
The antibody applied in Example 4 was the same as tha antibod~ of Example 3.
The recovery was 98~.
Example 5 \ Total Determination of Thyroxine by Enzymatic Hydrolysis with Pepsin The general working procedure of Example 1 was followed.
10 ~1 serum with a content of 18 ~g thyroxine per 100 ml were mixed with 160 ~1 of an enzyme solution, which consisted of 2 mg/ml pepsin dissolved in 0.1 n hydrochloric acid. The reaction with the enzyme was per-formed at room temperature for 30 minutes.
To this 170 ~1 subsequently 150 ~1 tracer solu-tion with a content of 5.2 ng/ml of radioactive marked thyroxine were added.
The entire solution was then added to 60 mg of an antibody gel. The polymer matrix of the antibody gel con-sisted of a copolymer of acrylamide and 40 mole ~ of the sodium salt of methacrylic acid, prepared from a 20% monoO
mer solution.
The incubation time was 30 minutes, the temperature 22C.
An extraction followed for 5 minutes at a pumping rate of 0.5 ml/min.
The evaluation showed a recovery of 98~.
' !
'', . ' ' ..
. ' ' :' ' ' '
Methods of the total determination of hormones through the enzymatic hydrolysis of the bonding proteins and with radioimmunological techniques are known from J.Clin. Endocrinol. Metab. 42, 189, 1976 and Clinical Chemistry, Vol 22, No. 11, 1976, p. 1850. These articles show that enzymatic cleavage has significant advantages \ compared with methods used heretofore, such as, for example, solvent extraction and heat denaturation. Advantages specifically named are the facts that extraction with organic solvents and the chromatographic purification of samples are eliminated,thatthe time and expense of the determination is reduced, that scinitallation counting in the liquid is eliminated, that specificity and accuracy is improved, that the method of determination can be automated, and that the method is universally applicable.
However, the enzyme used to hydrolyze the bonding protein also attacks the antibody introduced in the next working step and destroys the latter. For this reason, the enzyme must be deactivated prior to the addition of said antibody. Inactivation of enzymatic activity is pos-sible in a number of ways, for example, the enzyme can be denaturated by a substantial change in the pH value or by a heat effect.
However, this denaturization step is extremely disadvantageous. It requires either the addition of supplemental chemicals which introduces still more factors of interference in the system or it re~uires long periods of time for heat denaturization. The heat effect must last for approximately 5 minutes, while the cooling period amounts to approximately 15 minutes. This denaturization step thus represents a substantial hindrance in the automation of the determination. Further, depending on the system applied, specifically the enzyme used, different types of dena-turization must be performed, which opposes the general applicability of -the method of determination and its automation.
SUMMARY OF THE INVENTION
To avoid the difficulties of the prior art, the present invention creates a method for the total determina-tion of hormones and pharmaceuticals in which no denaturing step is necessary. Thus, it is an object of the invention to renderthe method of determination universally applic-able, to reduce the time and expense of the determination and to make possible the automation of the determination.
According to the invention, the object is attained \ by a method for the total determination of hormones and pharmaceuticals partially bound to specific or non-specific proteins, by the enzymatic hydrolysis of the bonding pro-teins, the reaction of said hormones or pharmaceuticals with an antibody and the radioimmunological determination of the hormones and pharmaceuticals, characterized by the fact that immobilized antibodies are used.
The antibody is preferably enclosed in a polymer gel. Acrylamide polymers and acrylamide copolymers are particularly preferred as the polymer gel. Specific advan-tages of copolymers are described in greater detail in Applicant's related application The application of immobilized antibodies pro-tects the an-tibodies from the enzyme. The antibodies are included in the polymer matrix which the enzyme, because of its size, cannot penetrate. As a resul-t of this simple and elegant measure in the process of the invention, the step of denaturing the enzyme may be eliminated. The process thus involves significantly less labor and requires less time. The method is universally applicable to different systems, because the specific enzyme denaturiza-tion is eliminated. Furthermore, the process of the invention is of particular importance, as it lends itself especially well to the automation of the determination.
6'7~
DETAIiED DESCRIPTION OF THE INVENTION
The method of the invention is suitable for the determination of different hormones and pharmaceu-ticals, which are present in the serum or the plasma in a state bound in part to specific or non-specific bonding proteins.
The hormones to be determined are thyroid hormones, particularly thyroxine and tri-iodothyroxin, the steroid hormones such as cortisol, testosterone, progesterone, estron, estradiol and estriol and the heart glycosides, such as digitoxin and digoxin. Further, vi-tamins, particularly Vitamin B12 and folic acid, as well as \ pharmaceuticals with strong protein bonds, such as, for example, anti-coagulants, dicumarol, analgetics and salycilates, may be determined.
In the execution of the determination, the serum or plasma containing the hormone or pharmaceutical is placed in contact with a solution of an enzyme, the enzyme hydrolytically cleaving the bonding protein. The choice of the enzyme is directed by the specific bonding protein.
For example, the following enzymes may be used depending on the system: aminopeptidase, bromelin, carboxypeptidase, chymotripsin, elastase, ficin, leucinaminopeptidase, lipase, pancreatin, papin, pepsin, pronase, protease, proteunase, thermolysin and trypsin. For the determination of hormones such as thyroxin and cortisol, proteolytic enzymes such as proteinase, pronase or pepsin are particularly suitable.
The reaction of the sample wi-th enzymatic solution can be performed on a controlled temperature means at temperatures around 35C or a room temperature. The period of time required for the enzymatic hydrolysis of the protein depends on the enzyme used and is between 15 minutes and 4 hours, in many cases between 15 and 30 minutes.
Following the hydrolysis of the protein, the sample is mixed with a marked indicator hapten and added to the immobilized antibody.
The addition is effected with the aid of a multi-channel piston pump. With the pump running in reverse, the reaction ]mixture is suctioned quantitatively into s~
small columns, said columns containing the immobilized antibody. ~n especially suitable apparatus for this is described in Applicant's copending application Subsequently, a rest interval is provided for the reaction of the marked and unmarked substance to be deter-mined with the immobilized antibody.
A final extraction with water or a buffer solu-tion yields the separation of haptenebound to the antibody and the free haptene. The resi~dual radioactivity in the extract or the column is a measure o~ the concentration of \ the substance to be determined. The radioimmunological principle is known, for example, from D. S. Skelley et al, Clinical Chemistry, Vol. 19, No. 2, 1973, p. 146ff.
Alternative methods of determination, such as fluoroimmunological determination or determination by enzymatic marking, may also be used.
The synthesis of antigenes, the production of antisera, for example, through the immunication of rabbits and the isolation and immobilization of antibodies, are known ~see for example, D. S. Skelley et al., Clinical Chemistry, Vol. 19, No. 2, 1973, p. 146ff.
Immobilized antibodies are produced, for example, by adding a solution of the antibody to a monomer mixture.
The mixture is subjected to conditions of free radical polymerization and the polymer obtained is comminuted, washed and dried. Acrylamide is particularly suitable as the monomer. By copolymerizing the acrylamide with acryl derivatives with different functional groups, such as, for example, acrylic acid, methacrylic acid and methacrylamide, advantageous variations of the matrix may be obtained. Through the addition of copolymers, particu-larly the hydrophobicity and the charge of the matrix, can be affected and thus, the reaction of the antibody with the hormone or pharmaceutical to be determined, influenced.
In order to obtain a suitable pore size of the polymer matrix, the monomer concentration is varied. A
monomer concentration in the range of about 20% results in a pore size of about 7 to 10 A.
The use of an ~on-exchanged polymer matrix is also advantageousO The buffer action obtained by the ion exchange can be used to alter the p~ values in the sample to be determined~ An advantageous system is, for example, a copolymer of acrylamide and 20 to 60% acrylic acid and/
or methacrylic acid, prepared from an approximately 20%
monomer solution in which at least part of the acid groups are converted into the corresponding alkali or alkaline earth salts.
The invention will be explained hereafter in more detail with the aid of examples \ Example 1 '~ Determination of Thyroxin by Enzymatic Hydrolysis with Pronase 1~ The antigen synthesis was performed beginning with thyroxine ethyl ester and coupling on albumin with carbodiimide. The antibody was produced through the immunization of rabbits.
The antibody was then enclosed in polymer gel.
An acrylamide monomer with a concentration of 2.9 mole/l was used. For the initial mixture, 5 g acrylamide and 1.25 g N,N'-methylene-bis-acrylamide were dissolved in a beaker in 24 ml of a phosphate buffer with a pH value of 7.2.
Following the admixture of the antiserum in 1 ml phosphate buffer, the reaction was started with 0.15 g riboflavin and 0.10 ml N,N,N',N'-tetramethylethylenediamine and irradiated with W light. ~uring the irradiation period of 45 minutes the temperature was maintained at less than 50C. The gel block was subsequently comminu-ted, washed with distilled water, and dried.
The zero serum was produced by reacting 1 ml serum and a pronase solution with a concentration of 2 mg/
ml for 30 minutes at 35C. Subsequently, 2 g of an ion exchange resin (Amberlite 400) were added.
After this, 50 ~1 of the zero serum with a content of 18 g thyroxine per 100 ml were reacted with 350 ~1 enzyme solution with a concentration of 2 mg per ml for 30 minutes at a temperature of 35C.
' ' . .
- ~' ~CI 675~3 To L00 ~1 of this solution, 700 ~1 of the tracer solution w ~h a content of 5.2 ng/ml of radioactive marked thyroxine and 50 ~1 buffer solution with a pH value of 7.2 were added. 350 ~1 of this solution were added to 60 mg of the antibody gel. The incubation period was 30 minutes, the temperature 22~C. ~ubsequently, the solution was extracted for 5 minutes~with a pumping rate of 0.5 ml/min.
A dose effect curve for thyroxine was established with thyroxine solutions having concentrations of 5 ng, 10 ng, 20 ng and 50 ng per 100 ml. These solutions were reacted with 350 ~1 enzyme solution (concentration 2 mg/ml) for 30 minutes at a temperature of 35C.
To the 100 ~1 of this solution, 700 ~1 tracer solution (5.2 ng/ml) and in place of the buffer, 50 ~1 zero serum were added.
The evaluation resulted in a recovery of 99~.
Example 2 Total Determination of Thyroxine by Enzymatic Hydrolysis with Proteinase The working procedure of Example 1 was followed, but instead of the pronase solution, a proteinase solu-tion with a concentration of 2 mg/ml was used.
The serum applied consisted of a zero serum with a content of 6 mg per 100 ml.
The recovery was 98.5%.
Example 3 Total Determination of Cortisol by Enzymatic Hydrolysis with Pronase The procedure of Example 1 was followed, but a 30 serum containing 18 ~g cortisol per 100 ml was used. As the tracer soiution, a solution of radioactive marked cortisol in a concentration of 0.15 ng/ml was used. The antibody used was prepared by the synthesis of cortisol-C3-oxime and coupling at albumin with mixed anhydride and antibody procluction through the immunication of rabbits.
The recovery was 97%.
, :, ., ., ~. . --~6~7S~
Example 4 Total Determination of Cortisol by Enzymatic Hydrolysis with Proteinase The working procedure of Example 3 was followed, but the serum contained 6 ~g cortisol per 100 ml and a proteinase solution with a conc:entration of 2 mg/ml was used.
The antibody applied in Example 4 was the same as tha antibod~ of Example 3.
The recovery was 98~.
Example 5 \ Total Determination of Thyroxine by Enzymatic Hydrolysis with Pepsin The general working procedure of Example 1 was followed.
10 ~1 serum with a content of 18 ~g thyroxine per 100 ml were mixed with 160 ~1 of an enzyme solution, which consisted of 2 mg/ml pepsin dissolved in 0.1 n hydrochloric acid. The reaction with the enzyme was per-formed at room temperature for 30 minutes.
To this 170 ~1 subsequently 150 ~1 tracer solu-tion with a content of 5.2 ng/ml of radioactive marked thyroxine were added.
The entire solution was then added to 60 mg of an antibody gel. The polymer matrix of the antibody gel con-sisted of a copolymer of acrylamide and 40 mole ~ of the sodium salt of methacrylic acid, prepared from a 20% monoO
mer solution.
The incubation time was 30 minutes, the temperature 22C.
An extraction followed for 5 minutes at a pumping rate of 0.5 ml/min.
The evaluation showed a recovery of 98~.
' !
'', . ' ' ..
. ' ' :' ' ' '
Claims (3)
1. In a process for the total determination of hormones and pharmaceuticals bonded partially to specific or non-specific bonding proteins in a sample, by the enzymatic hydrolysis of the bonding proteins, the reaction of the hormones or pharmaceuticals with an antibody and the radioimmunological determination of the hormones or pharmaceuticals, the improvement comprising the use of immobilized antibodies in a polymeric matrix which the enzyme, because of its size, cannot penetrate, and the sample being mixed with a marked indicator hapten following hydrolysis prior to being added to the immobilized antibodies.
2. A process as claimed in claim 1 wherein said antibodies are enclosed in a polymer gel.
3. A process as claimed in claim 1 or 2 wherein the antibodies are enclosed in an acrylamide polymer or acrylamide copolymer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP2718700.4 | 1977-04-27 | ||
| DE19772718700 DE2718700A1 (en) | 1977-04-27 | 1977-04-27 | METHOD FOR TOTAL DETERMINATION OF HORMONES AND PHARMACA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1106758A true CA1106758A (en) | 1981-08-11 |
Family
ID=6007401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA302,081A Expired CA1106758A (en) | 1977-04-27 | 1978-04-26 | Process for the total determination of hormones and pharmaceuticals by enzymatic hydrolysis and use of immobilized antibodies |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4235866A (en) |
| JP (1) | JPS5417115A (en) |
| AT (1) | AT357691B (en) |
| AU (1) | AU518437B2 (en) |
| BE (1) | BE866488A (en) |
| BR (1) | BR7802597A (en) |
| CA (1) | CA1106758A (en) |
| CH (1) | CH640060A5 (en) |
| CS (1) | CS200547B2 (en) |
| DD (1) | DD136428A5 (en) |
| DE (1) | DE2718700A1 (en) |
| DK (1) | DK181278A (en) |
| FI (1) | FI781218A (en) |
| FR (1) | FR2389136A1 (en) |
| GB (1) | GB1603774A (en) |
| GR (1) | GR64472B (en) |
| HU (1) | HU177804B (en) |
| IE (1) | IE46807B1 (en) |
| IL (1) | IL54556A (en) |
| LU (1) | LU79536A1 (en) |
| NL (1) | NL7804464A (en) |
| NO (1) | NO781471L (en) |
| NZ (1) | NZ187069A (en) |
| PL (1) | PL110972B1 (en) |
| SE (1) | SE7804799L (en) |
| ZA (1) | ZA782360B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3168691D1 (en) * | 1980-11-07 | 1985-03-14 | Technicon Instr | Immunoassay of proteins |
| US4452903A (en) * | 1981-02-17 | 1984-06-05 | Lee Jin P | Assay method and reagent kit means for lipid-containing body fluid |
| US4393040A (en) * | 1981-03-24 | 1983-07-12 | Lopapa Institute, Inc. | In-vitro diagnostic method for detection of acetylsalicylic acid ingestion |
| US4659655A (en) * | 1981-11-25 | 1987-04-21 | Bio-Response, Inc. | Method for isolating product-producing cells |
| US4790919A (en) * | 1984-06-28 | 1988-12-13 | E. I. Du Pont De Nemours And Company | Process for preparation of electrophoresis gel material |
| NZ217821A (en) * | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
| US5807832A (en) * | 1987-06-09 | 1998-09-15 | Biotech Australia Pty Limited | Oral delivery of biologically active substances bound to vitamin B12 |
| JP2523171B2 (en) * | 1987-08-12 | 1996-08-07 | 帝人株式会社 | Immunoassay method and reagent kit used therefor |
| NZ242220A (en) * | 1991-04-02 | 1994-04-27 | Biotech Australia Pty Ltd | Complex for oral delivery of a substance to the circulatory or lymphatic drainage system comprising microparticle coupled to at least one carrier, the substance being encapsulated by the microparticle |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1054050A (en) * | 1973-05-01 | 1979-05-08 | Stuart J. Updike | Gel column device and use in blood purification and immunoassay |
| US3925017A (en) * | 1973-05-01 | 1975-12-09 | Wisconsin Alumni Res Found | Preparation of dry, porous gel particles having high water regain for liquid sampling |
| US3962039A (en) * | 1974-08-08 | 1976-06-08 | Center For Laboratory Medicine | Analytical procedure for thyroid hormones |
| US4061466A (en) * | 1974-10-16 | 1977-12-06 | Ingvar Gosta Holger Sjoholm | Biologically active composition and the use thereof |
| GB1524372A (en) * | 1975-01-09 | 1978-09-13 | Radiochemical Centre Ltd | Radioassay of oestrogens |
-
1977
- 1977-04-27 DE DE19772718700 patent/DE2718700A1/en not_active Ceased
-
1978
- 1978-04-19 GR GR56023A patent/GR64472B/en unknown
- 1978-04-20 FI FI781218A patent/FI781218A/en not_active Application Discontinuation
- 1978-04-20 IL IL54556A patent/IL54556A/en unknown
- 1978-04-21 AU AU35365/78A patent/AU518437B2/en not_active Expired
- 1978-04-24 US US05/899,742 patent/US4235866A/en not_active Expired - Lifetime
- 1978-04-24 AT AT290778A patent/AT357691B/en not_active IP Right Cessation
- 1978-04-25 ZA ZA00782360A patent/ZA782360B/en unknown
- 1978-04-26 CH CH453878A patent/CH640060A5/en not_active IP Right Cessation
- 1978-04-26 CA CA302,081A patent/CA1106758A/en not_active Expired
- 1978-04-26 NL NL7804464A patent/NL7804464A/en not_active Application Discontinuation
- 1978-04-26 NZ NZ187069A patent/NZ187069A/en unknown
- 1978-04-26 LU LU79536A patent/LU79536A1/en unknown
- 1978-04-26 FR FR7812342A patent/FR2389136A1/en active Granted
- 1978-04-26 NO NO781471A patent/NO781471L/en unknown
- 1978-04-26 SE SE7804799A patent/SE7804799L/en unknown
- 1978-04-26 DK DK181278A patent/DK181278A/en not_active Application Discontinuation
- 1978-04-26 BR BR7802597A patent/BR7802597A/en unknown
- 1978-04-27 PL PL1978206414A patent/PL110972B1/en unknown
- 1978-04-27 DD DD78205050A patent/DD136428A5/en unknown
- 1978-04-27 IE IE833/78A patent/IE46807B1/en unknown
- 1978-04-27 CS CS782719A patent/CS200547B2/en unknown
- 1978-04-27 BE BE187206A patent/BE866488A/en not_active IP Right Cessation
- 1978-04-27 GB GB16824/78A patent/GB1603774A/en not_active Expired
- 1978-04-27 JP JP5072478A patent/JPS5417115A/en active Granted
- 1978-04-27 HU HU78CA422A patent/HU177804B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3536578A (en) | 1979-10-25 |
| PL206414A1 (en) | 1979-01-15 |
| JPS5417115A (en) | 1979-02-08 |
| DE2718700A1 (en) | 1978-11-02 |
| BE866488A (en) | 1978-08-14 |
| CS200547B2 (en) | 1980-09-15 |
| NZ187069A (en) | 1980-12-19 |
| HU177804B (en) | 1981-12-28 |
| ATA290778A (en) | 1979-12-15 |
| LU79536A1 (en) | 1978-09-29 |
| FR2389136B1 (en) | 1984-05-04 |
| GR64472B (en) | 1980-03-27 |
| ZA782360B (en) | 1979-04-25 |
| FR2389136A1 (en) | 1978-11-24 |
| AT357691B (en) | 1980-07-25 |
| NO781471L (en) | 1978-10-30 |
| JPS6217189B2 (en) | 1987-04-16 |
| IL54556A (en) | 1983-03-31 |
| IL54556A0 (en) | 1978-07-31 |
| IE46807B1 (en) | 1983-09-21 |
| DD136428A5 (en) | 1979-07-04 |
| US4235866A (en) | 1980-11-25 |
| BR7802597A (en) | 1978-12-19 |
| DK181278A (en) | 1978-10-28 |
| SE7804799L (en) | 1978-10-28 |
| GB1603774A (en) | 1981-11-25 |
| FI781218A (en) | 1978-10-28 |
| NL7804464A (en) | 1978-10-31 |
| IE780833L (en) | 1978-10-27 |
| AU518437B2 (en) | 1981-10-01 |
| CH640060A5 (en) | 1983-12-15 |
| PL110972B1 (en) | 1980-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3966897A (en) | Medium for use in bioassay and method of using same | |
| US4578361A (en) | Creatinine antibody | |
| CA1106758A (en) | Process for the total determination of hormones and pharmaceuticals by enzymatic hydrolysis and use of immobilized antibodies | |
| US4343896A (en) | Method and test pack for the demonstration and determination of an antigen or antibody | |
| Everitt et al. | Mechanism of the arginine requirement for adenovirus synthesis: I. Synthesis of structural proteins | |
| WO1983000505A1 (en) | Assay for viruses | |
| JPH0116388B2 (en) | ||
| US4235867A (en) | Acrylamide copolymer matrix for radioimmune assay techniques | |
| US4235865A (en) | Method for the determination of unbound hormones and pharmaceuticals | |
| JPS6112547B2 (en) | ||
| John et al. | Effect of whole body x-irradiation of rats on net synthesis of albumin, fibrinogen, α1-acid glycoprotein, and α2-globulin (acute phase globulin) by the isolated, perfused rat liver | |
| US6010867A (en) | Reagent for biomaterials assay, preparation method thereof, and assay method | |
| Delorme et al. | Methodologic problems in plasma renin activity measurements | |
| US4510240A (en) | Homogeneous enzyme immunoassay with heating step after incubation, THERESIA | |
| JP2994739B2 (en) | Rapid measurement of trace components | |
| CA1113004A (en) | Antibody against acid phosphatase isoenzymes for detection of prostatic cancer | |
| TAKANASHI et al. | Fluorometric determination of pyridoxal and its 5′-phosphate in biological materials | |
| Gurd et al. | Immunochemical characterization of proteins from mouse liver plasma membranes | |
| AU606067B2 (en) | Initiation of antibody formation in vertebrates | |
| EP0085402B1 (en) | Method of determination of human urine kallikrein and kit for the same | |
| GB2062226A (en) | Reagent and method for the determination of human-muscle aldolase | |
| US4250253A (en) | Composition adapted for the determination of tri-iodo thyronine and diagnosis method employing same | |
| US3770584A (en) | Pronase purification | |
| Lee et al. | A direct radioimmunoassay for aldosterone in unextracted serum and plasma. | |
| US4393040A (en) | In-vitro diagnostic method for detection of acetylsalicylic acid ingestion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |